Organogenesis Stock (NASDAQ:ORGO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.47

52W Range

$2.04 - $7.08

50D Avg

$2.45

200D Avg

$3.82

Market Cap

$306.25M

Avg Vol (3M)

$1.48M

Beta

1.33

Div Yield

-

ORGO Company Profile


Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

869

IPO Date

Jan 05, 2017

Website

ORGO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Product$563.03M--
Grant$1.14M--
Advanced Wound care-$453.64M$405.51M
Surgical and Sports Medicine-$28.40M$27.63M

Fiscal year ends in Dec 25 | Currency in USD

ORGO Financial Summary


Dec 25Dec 24Dec 23
Revenue$564.17M$482.04M$433.14M
Operating Income$44.69M$-1.28M$12.53M
Net Income$56.91M$861.00K$4.95M
EBITDA$44.69M$15.76M$36.03M
Basic EPS$0.16$-0.01$0.04
Diluted EPS$0.15$-0.01$0.04

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 08, 26 | 12:00 AM
Q4 25Feb 26, 26 | 5:00 PM
Q3 25Nov 07, 25 | 5:00 PM

Peer Comparison


TickerCompany
CMPXCompass Therapeutics, Inc.
SNDLSNDL Inc.
EBSEmergent BioSolutions Inc.
BCYCBicycle Therapeutics plc
EOLSEvolus, Inc.
ESPREsperion Therapeutics, Inc.
ANGOAngioDynamics, Inc.
MNPRMonopar Therapeutics Inc.
VREXVarex Imaging Corporation
SIGASIGA Technologies, Inc.